MPI Reasearch Invests in Upgrades and Department Expansions
MPI Research plans to renovate more than 55,000 square feet of facility space as part of the company’s plan to invest in upgrades and department expansion.
MPI Research, an early-stage drug development contract research organization (CRO) based in Michigan, is investing more than $5 million in a facility renovation to begin in 2016. The company plans to renovate more than 55,000 square feet of facility space.
Ed Amat, executive vice-president of global sales and marketing, says in a press announcement that the expansion reflects the increasing demand for investigational and preclinical pharmaceutical and medical device studies. Amat also says that MPI plans to renovate the company’s clinical pathology lab.
In the upcoming year, MPI hopes to increase the company’s workforce by approximately 10%. The company also plans to expand its surgical department with upgraded suites and additional equipment capabilities.
Source: MPI
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
